Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Leslie W. Kreis Purchases 71,428 Shares

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) Director Leslie W. Kreis bought 71,428 shares of the stock in a transaction on Friday, June 27th. The shares were acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the acquisition, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This trade represents a 57.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Actuate Therapeutics Trading Down 3.2%

Shares of NASDAQ ACTU traded down $0.22 during mid-day trading on Thursday, reaching $6.53. 53,986 shares of the company's stock were exchanged, compared to its average volume of 58,310. The business has a fifty day simple moving average of $8.95 and a 200 day simple moving average of $8.27. Actuate Therapeutics, Inc. has a twelve month low of $5.50 and a twelve month high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).

Analysts Set New Price Targets

ACTU has been the topic of several analyst reports. HC Wainwright increased their target price on Actuate Therapeutics to $20.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. Craig Hallum initiated coverage on shares of Actuate Therapeutics in a research report on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 price target on the stock.

Institutional Investors Weigh In On Actuate Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ACTU. Goldman Sachs Group Inc. increased its holdings in Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock worth $151,000 after purchasing an additional 11,105 shares in the last quarter. Voss Capital LP boosted its position in shares of Actuate Therapeutics by 157.7% during the first quarter. Voss Capital LP now owns 142,381 shares of the company's stock worth $964,000 after buying an additional 87,135 shares during the period. Chicago Partners Investment Group LLC bought a new position in shares of Actuate Therapeutics during the first quarter worth about $70,000. Sfmg LLC bought a new position in shares of Actuate Therapeutics during the first quarter worth about $74,000. Finally, Sigma Planning Corp raised its position in Actuate Therapeutics by 47.3% in the 1st quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock valued at $160,000 after buying an additional 7,600 shares during the last quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.